In 2010, the United States Food and Drug Administration (FDA) issued a requisite for gonadotropin‐releasing hormone (GnRH) agonists, a main form of androgen deprivation therapy (ADT) for locally advanced and metastatic prostate cancer (PCa), to carry a safety warning on the drug labels after several observational studies,1, 2, 3, 4, 5, 6, 7 and a meta‐analysis of observational studies8 showed an increased risk of cardiovascular disease (CVD) in individuals on GnRH agonists. This evidence concerns the gene GNRH1 and metastatic prostate carcinoma.